Hematological Safety of Contezolid versus Linezolid in Stage 5 Chronic Kidney Disease: An Active-Comparator New-User...

Contezolid is a novel oxazolidinone antibiotic approved for treating Gram-positive bacterial infections. Unlike linezolid, it lacks myelosuppressive toxicity, a potential advantage in patients with renal failure who are prone to anemia. However, data on hematologic safety of contezolid in this population remains limited. This study evaluates the hematological effects of contezolid in patients with renal failure.

This two-center retrospective cohort study employed an active-comparator new-user design to compare the hematological safety of contezolid versus linezolid in patients with renal failure. The primary outcome was the impact of contezolid and linezolid on hemoglobin levels. The secondary outcomes included microbial eradication, clinical cure rate and adverse reaction. Propensity score matching and multivariate logistic regression were used to adjust for confounding factors.

A total of 290 patients were enrolled, with 122 in the contezolid group and 168 in the linezolid group. Severe anemia occurred in 14.75% of patients receiving contezolid versus 46.43% with linezolid (P < 0.001). No significant differences in platelet count (P = 0.072), clinical cure rate (P = 0.878), procalcitonin levels (P = 0.432), or microbial eradication rates (P = 0.411) were observed between the contezolid and linezolid groups after treatment. Multivariate-adjusted logistic analysis further illustrated that, compared to contezolid, linezolid was associated with a higher risk of severe anemia (adjusted odds ratio: 2.29; 95% CI: 1.64-3.35), with a treatment duration cutoff of 7 days.

Compared with linezolid, contezolid was associated with a lower risk of clinically significant hemoglobin decline among patients with renal failure.